|
°æ³²Á¦¾à |
[°æ³²Á¦¾à] ±âȹ,Àλç,¸¶ÄÉÆà °æ·Â»ç¿ø ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
ÇϹݱ⠻ç¿ø¸ðÁý |
1³â¡è |
ä¿ë½Ã |
07.26 |
|
|
Novotech |
Pharmacovigilance Associate (Snr)_Korean Speaker Only
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
1³â¡è |
ä¿ë½Ã |
03.13 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
(Sr.)RA Specialist 2¸í ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
05.13 |
|
|
¸Þµð°¡À̵å ÁÖ½Äȸ»ç |
ÀÇ·á±â±â ÄÁ¼³ÅÏÆ® (°æ·ÂÁ÷) ¸ðÁý
°æ±â ±¤¸í½Ã | Çз¹«°ü |
°ø°³Ã¤¿ë |
2³â¡è |
»ó½Ãä¿ë |
04.19 |
|
|
(ÁÖ)ÀÌÁö¼Ö·çÅØ |
GMPÀÎÁõ ÄÁ¼³ÅÏÆ® ¸ðÁý(ÀÇ·á±â±â)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
2³â¡è |
ä¿ë½Ã |
02.04 |
|
|
(ÁÖ)ÀÌÁö¼Ö·çÅØ |
GMP&Validation ä¿ë°ø°í
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
2³â¡è |
ä¿ë½Ã |
04.23 |
|
|
»ïÀÏÁ¦¾à(ÁÖ) |
¾È°ú/Á¦Á¦¿¬±¸¿ø °æ·Â»ç¿ø ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÇϹݱ⠻ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
01.19 |
|
|
Çѱ¹MSD ÁÖ½Äȸ»ç |
SCMÆÀ Assistance D&L Specialist 1¸í(1³â °è¾à±Ù¹«)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¼ö½Ãä¿ë |
2³â¡è |
ä¿ë½Ã |
05.12 |
|
|
ÁöÀÌÇコÄɾîÄÚ¸®¾Æ(ÁÖ) |
ÁöÀÌÇコÄɾîÄÚ¸®¾Æ(ÁÖ) Service Solutions Analyst »ç¿ø´ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
03.06 |
|
|
Janssen |
[Janssen] Project Manager (Local Trial Manager)
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
01.29 |
|
|
anssen |
[Janssen] Project Manager (Local Trial Manager)
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
01.31 |
|
|
(ÁÖ)Çѱ¹·Î½´ |
Onsite User Services Specialist
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÇϹݱ⠻ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
07.09 |
|
|
½á¸ðÇǼŻçÀ̾ðƼÇÈ ÄÚ¸®¾Æ |
Technical Sales Specialist for Imaging, Biosciences
¼¿ï °³²±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
02.16 |
|
|
Çѱ¹¾á¼¾ |
[Janssen] Medical Advisor - Solid Tumor Targeted Therapy
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
03.08 |
|
|
VUNO |
(ÁÖ)ºä³ë 2018 »ó¹Ý±â ä¿ë°ø°í(¿µ¾÷/ÀÎÇã°¡ ´ã´ç)
¼¿ï ¼Ãʱ¸, ¼¿ï ÀüÁö¿ª, ¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
03.23 |
|